Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 801–900 of 2,517
Lee, J.-G., Ahn, J., Kim, T. J., Lee, J. H., & Choi, J. (2015) · Scientific Reports · doi:10.1038/srep12642 · Cited by 72
P53 tumour suppressor gene and germ cell neoplasia
Lutzker, S. G. (1998) · Apmis · doi:10.1111/j.1699-0463.1998.tb01323.x · Cited by 57
“The central region (amino acids 100-300) contains a protease-resistant “core” domain which binds to well characterized DNA sequences upstream or within introns of p53-regulated genes (Cho et al. 1994).”
BackgroundThukral, S. K., Blain, G. C., Chang, K. K., & Fields, S. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.12.8315 · Cited by 60
Wolfe, S. A., Ferentz, A. E., Grantcharova, V., Churchill, M. E. A., & Verdine, G. L. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90271-6 · Cited by 59
Demma, M. J., Wong, S., Maxwell, E., & Dasmahapatra, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401854200 · Cited by 58
Tam, B., Sinha, S., & Wang, S. M. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.11.041 · Cited by 61
“Depending on the position in a protein, a residue modified by a genetic variant can have no, mild, or severe influ-ences on protein structure till inactivation of the affected protein [4–7].”
BackgroundMdm2: A Regulator of Cell Growth and Death
Alarcon-Vargas, D., Takahashi, S., & Ronai, Z. A. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)01001-7 · Cited by 65
Keil, M., Exner, T. E., & Brickmann, J. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.10361 · Cited by 64
p53 induces distinct epigenetic states at its direct target promoters
Vrba, L., Junk, D. J., Novak, P., & Futscher, B. W. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-486 · Cited by 58
“Most common p53 structure mutations appear in codons R175, G245, R249, and R282 [ 24 ].”
BackgroundInfluentialElevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.
Loging, W., & Reisman, D. (1999) · PubMed · Cited by 58
Rapakko, K., Allinen, M., Syrjäkoski, K., Vahteristo, P., Huusko, P., Vähäkangas, K., Eerola, H., Kainu, T., Kallioniemi, O.-P., Nevanlinna, H., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1530 · Cited by 58
“Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites”
BackgroundSong, H., Wu, J., Tang, Y., Dai, Y., Xiang, X., Li, Y., Wu, L., Wu, J., Liang, Y., Xing, Y., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9155 · Cited by 62
Bernard, X., Robinson, P., Nominé, Y., Masson, M., Charbonnier, S., Ramirez-Ramos, J. R., Deryckère, F., Travé, G., & Orfanoudakis, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025981 · Cited by 71
“The three-dimensional structure of the core domain bound to its double-stranded DNA target has unravelled the structural basis of p53 transcriptional activity [5].”
BackgroundRom, S., Gilad, A., Kalifa, Y., et al. (2005) · Biochimie · doi:10.1016/j.biochi.2005.11.008 · Cited by 57
p53, Aerobic Metabolism, and Cancer
Lago, C. U., Sung, H. J., Ma, W., Wang, P., & Hwang, P. M. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3650 · Cited by 66
“Three cysteine residues C176, C238, and C242 are tightly bound to zinc, which protects them from being oxidized, and their substitution by serine abolishes p53 activity (19, 96).”
BackgroundLi, Y., Mao, Y., Brandt-Rauf, P. W., Williams, A. C., & Fine, R. L. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0206 · Cited by 57
Zn2+-Dependent Misfolding of the p53 DNA Binding Domain
Butler, J. S., & Loh, S. N. (2007) · Biochemistry · doi:10.1021/bi062106y · Cited by 57
Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma
Yamazaki, Y., Chiba, I., Hirai, A., et al. (2002) · Oral Oncology · doi:10.1016/s1368-8375(02)00064-7 · Cited by 57
“Cys on the L2 loop is a ligand for the zinc, and Arg on the H2 helix contacts the major groove of the DNA [3].”
BackgroundInfluentialStructural and Functional Basis for Therapeutic Modulation of p53 Signaling
Bassett, E. A., Wang, W., Rastinejad, F., & El-Deiry, W. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1526 · Cited by 57
Inga, A., Monti, P., Fronza, G., Darden, T., & Resnick, M. A. (2001) · Oncogene · doi:10.1038/sj.onc.1204116 · Cited by 64
“The L1 loop backbone atoms are hydrogen bonded with the N-terminus of the H2 helix (Cho et al., 1994).”
BackgroundInfluentialRiethdorf, S., Friedrich, R. E., Ostwald, C., Batten, M., Gogacz, P., Gundlach, K. K. H., Schlechte, H. H., Becker, J. C., Bregenzer, T., Riethdorf, L., et al. (1997) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.1997.tb00222.x · Cited by 58
P53 Gene Alterations in Human Tumors: Perspectives for Cancer Control
Hollstein, M. C., Soussi, T., Thomas, G. D., von Brevern, M., & Bartsch, H. (1997) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-60393-8_26 · Cited by 62
Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy
Zhang, X., & Sjöblom, T. (2021) · Pharmaceuticals · doi:10.3390/ph14010057 · Cited by 66
“Codon 72 of the TP53 gene contains a well-known polymorphic site with the two alleles arginine and proline (Arg72Pro) [100].”
BackgroundChen, C., Gorlatova, N., Kelman, Z., & Herzberg, O. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013657108 · Cited by 55
“With the exception of the first structure (11), all p53DBD/DNA crystal structures exhibit the same dimer architecture.”
BackgroundKalvakolanu, D. V. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.01.002 · Cited by 59
“[341] Cho Y, Gorina S, Jeffrey PD, Pavletich NP.”
BackgroundEmamzadah, S., Tropia, L., & Halazonetis, T. D. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0351 · Cited by 55
Suad, O., Rozenberg, H., Brosh, R., Diskin-Posner, Y., Kessler, N., Shimon, L. J. W., Frolow, F., Liran, A., Rotter, V., & Shakked, Z. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.10.063 · Cited by 53
Gain of function of mutant p53: R282W on the peak?
Zhang, Y., Coillie, S. V., Fang, J.-Y., & Xu, J. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.8 · Cited by 60
TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection
Klinakis, A., & Rampias, T. N. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102905 · Cited by 62
“Crystal structures of the human p53 core DNA-binding domain in complex with DNA (PDB IDs: 1TSR and 4IBV) [10,11] were retrieved from the RCSB Protein Data Bank and used to assign secondary”
BackgroundMethodMa, B., Pan, Y., Zheng, J., Levine, A. J., & Nussinov, R. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm192 · Cited by 56
“The monomeric p53–DNA interaction is well established (5), and several possibilities for the p53 tetramer–DNA interactions have been discussed (5–8).”
BackgroundCyclin D1 protein expression and gene polymorphism in colorectal cancer
McKay, J., Douglas, J. J., Ross, V. G., Curran, S., Murray, G. I., Cassidy, J., & Initiative, O. B. O. T. A. C. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001001)88:1<58::aid-ijc9>3.0.co;2-q · Cited by 121
Lowry, D. F., Stancik, A., Shrestha, R. M., & Daughdrill, G. W. (2007) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21721 · Cited by 63
Abnormal expression of the ATM and TP53 genes in sporadic breast carcinomas.
Angèle, S., Treilleux, I., Tanière, P., Martel‐Planche, G., Vuillaume, M., Bailly, C., Bremond, A. G., Montesano, R., & Hall, J. A. (2000) · PubMed · Cited by 62
The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer
Soussi, T. (1996) · Molecular Medicine Today · doi:10.1016/1357-4310(96)88756-9 · Cited by 66
A comprehensive study of p53 protein
Patil, M. R., & Bihari, A. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30331 · Cited by 64
“Around 30% of alterations occur in six hot areas that occur in nearly all cancer forms (R175, G245, R248, R249, R273, and R282).(82) These mutations result in the accumulation of the mutant p53 protein, which is unable to bind downstream genes and the consensus double‐stranded DNA.”
BackgroundStructural and sequential context of p53: A review of experimental and theoretical evidence
Saha, T., Kar, R. K., & Sa, G. (2014) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2014.12.002 · Cited by 66
Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers
Ferraiuolo, M. A., Verduci, L., Blandino, G., & Strano, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050961 · Cited by 56
“p53 is a modular protein harboring four functional different domains [23]: the N-terminal domain or transactivation domain (NTD or TA) that includes a proline-rich region and a transcriptional activation domain essential for binding to transcription factors and regulators of p53 activity [24,25]; the core domain that…”
BackgroundTherapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia
Demir, S., Boldrin, E., Sun, Q., Hampp, S., Tausch, E., Eckert, C., Ebinger, M., Handgretinger, R., Kronnie, G. T., Wiesmüller, L., et al. (2020) · Haematologica · doi:10.3324/haematol.2018.199364 · Cited by 55
“affect the structural integrity and DNA-binding ability of p53, leading to accumulation of dysfunctional p53 protein and increased oncogenic potential.(10-13) TP53 mutations are found frequently, in up to 95% of carcinomas, typically in older patients.”
BackgroundCuff, A. L., & Martin, A. C. R. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.10.015 · Cited by 55
How NF-κB can be attracted by its cognate DNA
Tisné, C., Delepierre, M., & Hartmann, B. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3157 · Cited by 55
Harris, C. C. (1995) · Toxicology Letters · doi:10.1016/0378-4274(95)03643-1 · Cited by 62
p53 DNA binding can be modulated by factors that alter the conformational equilibrium
McLure, K. G., & Lee, P. W. K. (1999) · The EMBO Journal · doi:10.1093/emboj/18.3.763 · Cited by 53
“These mutants, called class II or structural p53 mutants, are reactive with the monoclonal antibody (mAb) PAb240, which defines the mutant conformation (Gannon et al., 1990; Cho et al., 1994; Friend, 1994).”
BackgroundMutant p53 oncogenicity: dominant-negative or gain-of-function?
Stein, Y., Aloni-Grinstein, R., & Rotter, V. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa117 · Cited by 53
Analysis, separation, and bioassay of pyrrolizidine alkaloids from comfrey (symphytum officinale)
Couet, C., Crews, C., & Hanley, A. B. (1996) · Natural Toxins · doi:10.1002/19960404nt3 · Cited by 64
Reuter, M., Schneider‐Mergener, J., Kupper, D., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.8.5213 · Cited by 54
Glasfeld, A., Koehler, A. N., Schumacher, M. A., et al. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2946 · Cited by 54
Serine phosphorylation in the NH2 terminus of p53 facilitates transactivation.
Mayr, G. A., Reed, M. J., Wang, P., Wang, Y., Schweds, J. F., & Tegtmeyer, P. (1995) · PubMed · Cited by 53
Up-regulation of specific NF 1 gene transcripts in sporadic pilocytic astrocytomas.
Platten, M., Giordano, M. J., Dirven, C. M. F., Gutmann, D. H., & Louis, D. N. (1996) · Europe PMC (PubMed Central) · Cited by 58
Hafsi, H., & Hainaut, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3771 · Cited by 53
“These observations anticipated those deduced from the crystal structure of the DNA binding core domain of p53, which was described by Pavletitch and colleagues in 1993 in the form of a complex with DNA (11).”
Influentialp53 in head and neck cancer: Functional consequences and environmental implications of TP53mutations
Peltonen, J. K., Helppi, H. M., Pääkkö, P. K., Turpeenniemi-Hujanen, T. M., & Vähäkangas, K. (2010) · Head & Neck Oncology · doi:10.1186/1758-3284-2-36 · Cited by 55
“The crystal structure of the core domain, solved in 1994, provides a template for understanding the nature of mutant p53 [20].”
BackgroundBeno, I., Rosenthal, K., Levitine, M., Shaulov, L., & Haran, T. E. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1044 · Cited by 52
“The CWWG region is the most conserved region of p53 REs (44), even though the WW dinucleotide is uncontacted in complex with p53DBD (12,13).”
BackgroundSmall Molecules That Target Protein Misfolding
Gavrin, L. K., Denny, R. A., & Saiah, E. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301182j · Cited by 57
Augustyn, K. E., Merino, E. J., & Barton, J. K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709326104 · Cited by 53
Goi, K., Takagi, M., Iwata, S., Delia, D., Asada, M., Donghi, R., Tsunematsu, Y., Nakazawa, S., Yamamoto, H., Yokota, J., et al. (1997) · PubMed · Cited by 61
Tarapore, P., Tokuyama, Y., Horn, H. F., & Fukasawa, K. (2001) · Oncogene · doi:10.1038/sj.onc.1204848 · Cited by 56
“Although both Arg175 and Arg249 residues lie within the central DNA binding domain, these residues do not directly contact the DNA, but are important for stabilizing the proper folding of the DNA binding domain (Cho et al., 1994).”
BackgroundYY1 binding to a subset of p53 DNA-target sites regulates p53-dependent transcription
Yakovleva, T., Kolesnikova, L., Vukojević, V. B., Павловна, Г. И., Tan–No, K., Austen, M., Lüscher, B., Ekström, T. J., Terenius, L. Y., & Bakalkin, G. Y. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.065 · Cited by 60
Similar outcome of elderly patients in Intergroup Trial 0096
Yuen, A. R., Zou, G., Turrisi, A. T., Sause, W. T., Komaki, R. R., Wagner, H., Aisner, S. C., Livingston, R. B., Blum, R. H., & Johnson, D. H. (2000) · Cancer · doi:10.1002/1097-0142(20001101)89:9<2006::aid-cncr18>3.0.co;2-7 · Cited by 140
Pina, S., Canadas, R. F., Jiménez, G., Perán, M., Marchal, J. A., Reis, R. L., & Oliveira, J. M. (2017) · Cells Tissues Organs · doi:10.1159/000469703 · Cited by 52
“It has also been reported to have antiangiogenic effects, by decreasing the expression of both the genes and growth factors involved in angiogenesis [Cho et al., 1994; Kandaz et al., 2009].”
BackgroundD'Abramo, M., Bešker, N., Desideri, A., Levine, A. J., Melino, G., & Chillemi, G. (2016) · Oncogene · doi:10.1038/onc.2015.388 · Cited by 51
p53 and p73 display common and distinct requirements for sequence specific binding to DNA
Lokshin, M., Li, Y., Gaiddon, C., & Prives, C. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1047 · Cited by 51
“A previous report has shown that treatment of cells with the metal chelator TPEN disrupts p53 conformation as assessed by immunoprecipitating with an antibody MAb 240 (29) that recognizes p53 in a partially unfolded mutant conformation (26,58).”
BackgroundDanziger, S. A., Zeng, J., Wang, Y., Brachmann, R. K., & Lathrop, R. H. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm166 · Cited by 57
“Attributes are generated from model p53 mutants constructed in silico from chain b of the wild-type p53 crystal structure ( Cho et al., 1994 ) using Amber molecular modeling software (Case et al., 2004).”
MethodIncreased p53 mutation frequency during tumor progression--results from a breast cancer cohort.
Norberg, T., Klaar, S., Kärf, G., et al. (2001) · PubMed · Cited by 52
Chen, G. G., Merchant, J. L., Lai, P. B. S., Ho, R. L. K., Hu, X., Okada, M., Huang, S. F., Chui, A. K. K., Law, D., Li, Y. G., et al. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64317-9 · Cited by 52
“Mutations in the central domain alter either the structural integrity of the domain or the amino acids that directly contact the DNA, as demonstrated by the study of the crystal structure of the p53 protein.(26) The N terminus of the p53 protein encoded by exons 2 to 4 has an abundance of acidic amino acids that are i…”
BackgroundThe Role of P53 in Human Cancer
Malkin, D. M. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1010636426860 · Cited by 62
Dehner, A., Klein, C., Hansen, S., Müller, L., Buchner, J., Schwaiger, M., & Kessler, H. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200501887 · Cited by 52
Janus, F., Albrechtsen, N., Knippschild, U., Wiesmüller, L., Große, F., & Deppert, W. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.2155 · Cited by 62
“The p53 core domain has a complex structure, as it is composed of two alpha-helical loop domains and a beta-sheet domain, compacted via metal (zinc) binding (6).”
BackgroundThe Rel family of eukaryotic transcription factors
Chytil, M., & Verdine, G. L. (1996) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(96)80100-x · Cited by 53
Reinke, V., & Lozano, G. (1997) · Radiation Research · doi:10.2307/3579567 · Cited by 58
Scotcher, J., Clarke, D. J., Weidt, S. K., Mackay, C. L., Hupp, T. R., Sadler, P. J., & Langridge-Smith, P. R. R. (2011) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-011-0088-x · Cited by 51
“Cys277 is a DNA-binding residue [7] and oxidation of this residue has been implicated in differential gene recognition [11].”
BackgroundMutational Analysis of the p53 Core Domain L1 Loop
Zupnick, A., & Prives, C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603387200 · Cited by 51
Synergy of Peptide and Sugar in O-GlcNAcase Substrate Recognition
Schimpl, M., Borodkin, V. S., Gray, L. J., & van Aalten, D. M. F. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.011 · Cited by 51
“A notable exception is the tumor suppressor protein p53, where the reported Ser149 O-GlcNAc site resides in a loop that is fully defined in the crystal 176 Chemistry & Biology 19, 173–178, February 24, 2012 ª2012 Else structure of the p53 DNA binding domain (Cho et al., 1994).”
BackgroundInfluentialStructure of p73 DNA-binding domain tetramer modulates p73 transactivation
Ethayathulla, A. S., Tse, P.-W., Monti, P., Nguyen, S., Inga, A., Fronza, G., & Viadiu, H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115463109 · Cited by 51
“SEDNTERP software was used to calculate the partial specific volume, buffer viscosity, and buffer density (15)”
BackgroundMethodAcquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes
Redman-Rivera, L. N., Shaver, T. M., Jin, H., Marshall, C. B., Schafer, J. M., Sheng, Q., Hongo, R. A., Beckermann, K. E., Wheeler, F. C., Lehmann, B. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25359-z · Cited by 51
Regulation of the c-met Proto-oncogene Promoter by p53
Seol, D., Chen, Q., Smith, M. L., & Zarnegar, R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.6.3565 · Cited by 51
Seidl, H., Kreimer-Erlacher, H., Bäck, B., Soyer, H. P., Kerl, H., Wolf, P., & Höfler, G. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01413.x · Cited by 58
Sasaki, D. Y., & Alam, T. M. (2000) · Chemistry of Materials · doi:10.1021/cm990737r · Cited by 51
Patel, S. V., George, R., Autore, F., Fraternali, F., Ladbury, J. E., & Nikolova, P. V. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn490 · Cited by 56
Structural Differences in the DNA Binding Domains of Human p53 and Its C. elegans Ortholog Cep-1
Huyen, Y., Jeffrey, P. D., Derry, W. B., Rothman, J. H., Pavletich, N. P., Stavridi, E. S., & Halazonetis, T. D. (2004) · Structure · doi:10.1016/j.str.2004.05.007 · Cited by 53
Self-citationInga, A., & Resnick, M. A. (2001) · Oncogene · doi:10.1038/sj.onc.1204457 · Cited by 62
“Interestingly, cysteine 277 directly contacts the DNA sequence in the major groove at the third base of the pentameric consensus (Cho et al., 1994).”
BackgroundInfluentialFailure of BRCA1 dysfunction to alter ovarian cancer survival.
Buller, R. E., Shahin, M. S., Geisler, J. P., et al. (2002) · PubMed · Cited by 51
THE CELLULAR AND MOLECULAR PATHOGENESIS OF COLORECTAL CANCER
Carethers, J. M. (1996) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(05)70272-7 · Cited by 57
Gao, W.-M., Mady, H. H., Yu, G.-Y., Siegfried, J. M., Luketich, J. D., Melhem, M. F., & Keohavong, P. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00035-7 · Cited by 54
Novel cancer therapy by reactivation of the p53 apoptosis pathway
Bykov, V. J. N., & Wiman, K. G. (2003) · Annals of Medicine · doi:10.1080/07853890310017152 · Cited by 59
Temperature sensitivity for conformation is an intrinsic property of wild-type p53
Hainaut, P., Butcher, S., & Milner, J. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.48 · Cited by 49
“The crystal structure of human p53 reveals that hydrophobic residues play a key role in the formation of the two frsheets which support the DNA-binding surface of p53 (Cho et al., 1994).”
Backgroundp53: DNA damage, DNA repair, and apoptosis
Götz, C., & Montenarh, M. (1995) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/bfb0048265 · Cited by 53
An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer
Kong, L., Meng, F., Zhou, P., Ge, R., Geng, X., Yang, Z., Guo, L., Zhang, L., Wang, J., Ma, J., et al. (2024) · 中国科学通报:英文版 · doi:10.1016/j.scib.2024.05.017 · Cited by 57
Structure of full‐length p53 tumor suppressor probed by chemical cross‐linking and mass spectrometry
Arlt, C., Ihling, C. H., & Sinz, A. (2015) · PROTEOMICS · doi:10.1002/pmic.201400549 · Cited by 49
“The majority of cancer-associated p53 mutations are located in the DBD and different single-point p53 mutants of the DBD have been studied by ion mobility MS (IMMS) [15].”
BackgroundInfluentialJha, A. K., Nikbakht, M., Jain, V., Sehgal, A., Capalash, N., & Kaur, J. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-1787-5 · Cited by 51
WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma
Zhukova, N., Ramaswamy, V., Remke, M., Martin, D. C., Castelo‐Branco, P., Zhang, C. H., Fraser, M. E., Tse, K., Poon, R. W. M., Shih, D. J. H., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0174-y · Cited by 57
“TP53 is mutated or deleted in over 50% of human cancers resulting in loss of p53-associated apoptosis, cell cycle arrest or DNA brake/repair response [11]; Loss of normal p53 function and resultant impaired G1 check point control correlates with increased resistance to both low- and high-dose ionizing radiation in sev…”
BackgroundSelf-citationThe Rich World of p53 DNA Binding Targets: The Role of DNA Structure
Brázda, V., & Fojta, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225605 · Cited by 55
“The crystal structure of the p53 core domain with a linear DNA target has shown the importance of individual amino acid residues interacting with DNA [72] and were verified several times [73–76].”
BackgroundKucab, J. E., Phillips, D. H., & Arlt, V. M. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07676.x · Cited by 50
“These are located in codons for amino acids which either bind directly to the DNA of target genes (R248, R273) or are critical for stabilising the interaction of p53 with DNA (R175, R282, G245) [37].”
Backgroundp53 Protein Is a Suppressor of Papillomavirus DNA Amplificational Replication
Lepik, D., Ilves, I., Kristjuhan, A., Maimets, T., & Ustav, M. (1998) · Journal of Virology · doi:10.1128/jvi.72.8.6822-6831.1998 · Cited by 50
“The DNA-binding domain of p53 has been shown to be the target for most of the missense mutations which inactivate the tumor suppressor function of this protein in cells (12).”
BackgroundKelavkar, U. P., & Badr, K. F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4378 · Cited by 51
Wong, M. P., Cheung, N., Yuen, S. T., Leung, S. Y., & Chung, L. P. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990611)81:6<851::aid-ijc2>3.0.co;2-d · Cited by 125
Mutant p53 proteins: Between loss and gain of function
Strano, S., Dell'Orso, S., Mongiovi, A. M., Monti, O., Lapi, E., Agostino, S. D., Fontemaggi, G., & Blandino, G. (2007) · Head & Neck · doi:10.1002/hed.20531 · Cited by 50
Padlewska, K., Ramoz, N., Cassonnet, P., RIOU, G. F., Barrois, M., Majewski, S., Croissant, O., Jabłońska, S., & Orth, G. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01515.x · Cited by 55
Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia
Thornton, P. D., Gruszka, A., Hamoudi, R., Atkinson, S., Kaczmarek, P. A., Morilla, R. M., Hilditch, B. L., A’Hern, R., Matutes, E., & Catovsky, D. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200325 · Cited by 56
Telomerase activation in colorectal carcinogenesis
Yan, P., Saraga, E. P., Bouzourene, H., Bosman, F. T., & Benhattar, J. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199910)189:2<207::aid-path424>3.0.co;2-h · Cited by 28
Sedláček, Z., Kodet, R., Kriz, V., Seemanová, E., Vodvarka, P., Wilgenbus, P., Mareš, J., Poustka, A. J., & Goetz, P. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.172 · Cited by 48
Lubin, D. J., Butler, J. S., & Loh, S. N. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.11.013 · Cited by 47
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.